Wallace M/LinkedIn
Jan 3, 2026, 14:08
Wallace M Shares a SWOT Analysis of Aqvesme’s FDA Approval
Wallace M, CEO and Founder of i3consult.com, shared on LinkedIn:
”FDA APPROVAL UPDATE: Aqvesme™ (mitapivat) for Thalassemia‑Related Anemia
The FDA approval of Aqvesme™ introduces the first oral, disease‑modifying therapy for anemia in adults with alpha‑ or beta‑thalassemia.
Our latest SWOT analysis explores the clinical significance and strategic implications of this milestone.
Read the full analysis.”
Stay updated with Hemostasis Today.
-
Oct 5, 2026, 22:55Steve Humphreys: A Big Thank You to BSHT for Providing Me With a Recent Skills Exchange Award
-
Oct 5, 2026, 22:52William McKeown: Great to Be in Istanbul for the Opening of the EHC 2026
-
Oct 5, 2026, 22:48Laura Quintas Lorenzo: A New Approach to Healthcare for von Willebrand Disease at EHC 2026
-
Oct 5, 2026, 22:46Anas Zayad: Pleased to Share Our New Review on Thrombosis in SCD and Beta Thalassemia
-
Oct 5, 2026, 22:44Cihan Ay: Honouring Eric Kandel and Eugene Braunwald at the Medical University of Vienna
-
Oct 5, 2026, 22:42Heather L. Gornik: Testing for Aortic and Arterial Thrombosis at VSS 2026
-
Oct 5, 2026, 22:34Hasan Abbas Zaheer: Honoured to Have Co-Authored One of the Four Reviews in The Lancet Thalassemia Series
-
Oct 5, 2026, 22:34Kamyar Shameli: Understanding the Coagulation Cascade – How Anticoagulants Prevent Blood Clots
-
Oct 5, 2026, 22:31Risika Samanta: Pediatric ITP in a 12-year-old – An Atypical Presentation without a Viral Prodrome